2023年全國碩士研究生考試考研英語一試題真題（含答案詳解+作文范文）_第1頁
已閱讀1頁，還剩9頁未讀， 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進行舉報或認(rèn)領(lǐng)

文檔簡介

1、PatientNameZhangChunyanReptDate23December2014TumTypeCervixsquamouscellcarcinoma(SCC)FadditionalinfmationpleaselogontotheInteractiveCancerExpler?TosetupyourInteractiveCancerExpleraccountcontactyoursalesrepresentativecall(

2、888)9883639.ElectronicallySignedbyJeffreyS.RossM.D.MedicalDirect|CLIANumber:22D2027531|23December2014FoundationMedicineInc.1502ndStreetCambridgeMA02141|1.888.988.3639page1of10DateofBirth04April1979MedicalFacilityMGHCance

3、rCenterBostonSpecimenReceived09December2014SexFemalederingPhysicianGeRongbinSpecimenSiteCervixFMICase#TRF072788AdditionalRecipientNotGivenDateofCollection30October2014MedicalRecd#42496BMedicalFacilityID#200203SpecimenTyp

4、eSlideSpecimenID9502612PathologistHongtuZhangABOUTTHETEST:FoundationOneisanextgenerationsequencing(NGS)basedassaythatidentifiesgenomicalterationswithinhundredsofcancerrelatedgenes.PATIENTRESULTSTUMTYPE:CERVIXSQUAMOUSCELL

5、CARCINOMA(SCC)2genomicalterationsGenomicAlterationsIdentified?STK11F354LAPCsplicesite7301GA2therapiesassociatedwithpotentialclinicalbenefit0therapiesassociatedwithlackofresponse3clinicaltrials?Facompletelistofthegenesass

6、ayedperfmancespecificationspleaserefertotheAppendix?SeeAppendixfdetailsTHERAPEUTICIMPLICATIONSGenomicAlterationsDetectedFDAApprovedTherapies(inpatient’stumtype)FDAApprovedTherapies(inanothertumtype)PotentialClinicalTrial

7、sSTK11F354LNoneEverolimusTemsirolimusYesseeclinicaltrialssectionAPCsplicesite7301GANoneNoneNoneNote:GenomicalterationsdetectedmaybeassociatedwithactivityofcertainFDAapproveddrugshowevertheagentslistedinthisreptmayhavevar

8、iedclinicalevidenceinthepatient’stumtype.Neitherthetherapeuticagentsnthetrialsidentifiedarerankedinderofpotentialpredictedefficacyfthispatientnaretheyrankedinderoflevelofevidencefthispatient’stumtype.ZhangChunyanZhangChu

9、nyan04AprilFemaleTRF07242496B9502612950261GeRongbinNotGiven200203HongtuZhangggPatientNameZhangChunyanReptDate23December2014TumTypeCervixsquamouscellcarcinoma(SCC)FadditionalinfmationpleaselogontotheInteractiveCancerExple

10、r?TosetupyourInteractiveCancerExpleraccountcontactyoursalesrepresentativecall(888)9883639.ElectronicallySignedbyJeffreyS.RossM.D.MedicalDirect|CLIANumber:22D2027531|23December2014FoundationMedicineInc.1502ndStreetCambrid

11、geMA02141|1.888.988.3639page3of10THERAPIESTherearenotherapiesFDAapprovedinthispatientstumtypethatarespecifictothereptedgenomicalterations.ADDITIONALTHERAPIES–FDAAPPROVEDINOTHERTUMTYPESTHERAPYRATIONALEEverolimusEverolimus

12、isanallyavailablemTinhibitthathasbeenapprovedfuseinrenalcellcarcinomapancreaticneuroendocrinetumssubependymalgiantcellastrocytomaassociatedwithTSChmonereceptpositiveHer2negativeadvancedbreastcancer.AslossofLKB1activatest

13、hemTpathwaytherapiesthatinhibitmTmaybebeneficialftreatingtumswithalterationsinSTK111.APeutzJeghersSyndromepatientwithpancreaticcanceranSTK11mutationhadapartialresponsetothemTinhibiteverolimus19.Everolimusiscurrentlyincli

14、nicaltrialsinmultipletumtypes.Apreclinicalstudyevaluatingeverolimusincombinationwithcytotoxicchemotherapiesinxenograftmodelsthatincludedacervicalcancermodeldemonstratedmodestincreasedresponseoverchemotherapiesalonewithou

15、tmarkedlyincreasedtoxicities32.APhase2studyofeverolimustherapyhasreptednoobjectiveresponsesinanyof9patientswithrefractyheadnecksquamouscellcarcinoma(Varadarajanetal.2012OAbstract5541).APhase1trialinpatientswithadvancedso

16、lidtumshasreptedthateverolimusincombinationwithlowdoseweeklycisplatinshowedactivityinseveraltumtypeswiththreepartialresponsesprolongedstablediseaseobservedinfivepatientsoutof28evaluablepatientsoneopharyngealsquamouscellc

17、arcinomapatientobtainedstablediseaseaftermethan6cyclesoftreatments17.TemsirolimusTemsirolimusisanintravenousmTinhibitthathasbeenapprovedfuseinadvancedrenalcellcarcinoma.AslossofLKB1activatesthemTpathwaytherapiesthatinhib

18、itmTmaybebeneficialftreatingtumswithalterationsinSTK111.Temsirolimusiscurrentlyinclinicaltrialsinmultipletumtypes.APhase1trialoftemsirolimustopotecaninpatientswithgynecologicaltumsdemonstratedanacceptablesafetyprofiletha

19、tincludeddoselimitingmyelosuppressioninwomenwithoutpreviousradiationtherapy33.APhase2studyoftemsirolimusinpatientswithrecurrentmetastaticcervicalcarcinomahasreptedapartialresponsein3%(133)ofpatientsstablediseasein57.6%(1

20、933)ofpatientswithmildtomoderateadverseeffectsnotoxicitiesgreaterthangrade334.APhase1studyoftemsirolimusincombinationwithcarboplatinpaclitaxelin18patientswithHNSCCreptedapartialresponserateof22%35.HoweveraPhase2studyofte

21、msirolimuserlotinibinHNSCCwaspolytoleratedendedearly36.APhase1trialofbevacizumabtemsirolimusplusliposomaldoxubicininpatientswithadvancedsolidtumsshowedthatthecombinationwaswelltoleratedrepted21%(28136)ofpatientshavingsta

22、blediseasefatleastsixmonths21%(29136)ofpatientsexhibitingpartialcompleteremission18.GenomicalterationsdetectedmaybeassociatedwithactivityofcertainFDAapproveddrugshowevertheagentslistedinthisreptmayhavelittlenoevidenceint

溫馨提示

  • 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 眾賞文庫僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論